CD28 and myeloid sarcoma: This discovery together with our data on the critical role of the CD28/PI3K/c-myc axis in regulating the glycolytic metabolism of inflammatory T lymphocytes may provide the bases for the development of more efficient immunotherapeutic programs that target CD28 and associated signaling molecule in order to suppress excessive inflammation in MS.